< >

HyperAcute™ Immunotherapy

NewLink Genetics has multiple HyperAcute™ immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics' Independent Review Committee Recommends Study Continuation Without Modification After Completion of First Interim Analysis of IMPRESS Phase 3 Pancreatic Cancer Trial With Algenpantucel-L
March 07, 2014

NewLink Genetics Appoints Eugene P. Kennedy, M.D., as Vice President for Clinical and Medical Affairs
February 26, 2014

Read more news
ANNOUNCEMENTS
©2013 New Link Genetics, Inc. All rights reserved.
Site Map       Terms & Conditions       Privacy Policy       Contact Us